That's a good number for a globally marketable product. I read that Genoya for AIDS generated $4.8B USD in 2018 and Truvada, by the same company, Gilead, gener

That's a good number for a globally marketable product. I read that Genoya for AIDS generated $4.8B USD in 2018 and Truvada, by the same company, Gilead, generated another $3B USD. So that's almost $8B per year and Truvada has a 3 year CAGR of 82% so it's really grabbing market share. To your point there are other companies with competitive products but Gilead seems to be the leader. My point is simply that one model, drugs at 8B per year, assumes a continuous disease state while the other at 5B per year assumes a continuous reduction in diseased hosts as was seen with Polio, Smallpox and until recently +measles for example. One is better for the corporation. The other better for the commons. That's all I got. +Measles was declared eradicated, in the USA, early in this century.